MX2017007231A - Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos. - Google Patents
Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos.Info
- Publication number
- MX2017007231A MX2017007231A MX2017007231A MX2017007231A MX2017007231A MX 2017007231 A MX2017007231 A MX 2017007231A MX 2017007231 A MX2017007231 A MX 2017007231A MX 2017007231 A MX2017007231 A MX 2017007231A MX 2017007231 A MX2017007231 A MX 2017007231A
- Authority
- MX
- Mexico
- Prior art keywords
- staphylococcus aureus
- aureus antibody
- conjugates
- rifamycin
- rifamycin conjugates
- Prior art date
Links
- 229930189077 Rifamycin Natural products 0.000 title 1
- 230000000941 anti-staphylcoccal effect Effects 0.000 title 1
- 229960003292 rifamycin Drugs 0.000 title 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 title 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087213P | 2014-12-03 | 2014-12-03 | |
| PCT/US2015/063515 WO2016090040A1 (en) | 2014-12-03 | 2015-12-02 | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017007231A true MX2017007231A (es) | 2017-11-08 |
Family
ID=55022690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007231A MX2017007231A (es) | 2014-12-03 | 2015-12-02 | Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20180125995A1 (OSRAM) |
| EP (1) | EP3226908A1 (OSRAM) |
| JP (1) | JP6751393B2 (OSRAM) |
| KR (1) | KR20170086542A (OSRAM) |
| CN (1) | CN107249642A (OSRAM) |
| BR (1) | BR112017011478A2 (OSRAM) |
| CA (1) | CA2966211A1 (OSRAM) |
| HK (1) | HK1244230A1 (OSRAM) |
| MX (1) | MX2017007231A (OSRAM) |
| RU (1) | RU2017118792A (OSRAM) |
| WO (1) | WO2016090040A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015095227A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
| HK1222577A1 (zh) | 2013-12-16 | 2017-07-07 | Genentech Inc. | 擬肽化合物及其抗體藥物偶聯物 |
| CN108064246A (zh) | 2015-06-15 | 2018-05-22 | 基因泰克公司 | 抗体和免疫结合物 |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| CN108367043A (zh) | 2015-12-04 | 2018-08-03 | 西雅图基因公司 | 季铵化的微管溶素化合物的缀合物 |
| US10336683B2 (en) * | 2016-03-04 | 2019-07-02 | Genentech, Inc. | Process for the preparation of an antibody-rifamycin conjugate |
| KR20250114431A (ko) | 2016-11-08 | 2025-07-29 | 리제너론 파마슈티칼스 인코포레이티드 | 스테로이드 및 이의 단백질-접합체 |
| CN110944718A (zh) | 2017-05-18 | 2020-03-31 | 里珍纳龙药品有限公司 | 环糊精蛋白质药物偶联物 |
| CA3080857A1 (en) | 2017-11-07 | 2019-05-16 | Regeneron Pharmaceuticals, Inc. | Hydrophilic linkers for antibody drug conjugates |
| JP7366028B2 (ja) | 2018-01-08 | 2023-10-20 | レゲネロン ファーマシューティカルス，インコーポレーテッド | ステロイド及びその抗体コンジュゲート |
| KR20210008008A (ko) | 2018-05-09 | 2021-01-20 | 리제너론 파마슈티칼스 인코포레이티드 | 항-msr1 항체 및 이의 사용 방법 |
| CN111939256B (zh) * | 2020-07-06 | 2022-05-31 | 中国药科大学 | 一种具有细菌调理特性的抗菌辅助材料及其制备方法和应用 |
| EP4387618A4 (en) * | 2021-08-20 | 2025-07-09 | Univ Rutgers | DUAL-TARGETED RNA POLYMERASE INHIBITORS: CONJUGATES OF BENZOXAZINO- AND SPIRO-RIFAMYCINS WITH N-AROYL- N-ARYL-PHENYLALANINAMIDES |
| WO2023028593A2 (en) * | 2021-08-27 | 2023-03-02 | University Of Georgia Research Foundation, Inc. | Targeted nanoparticles and their uses related to infectious disease |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB877732A (en) | 1958-08-12 | 1961-09-20 | Lepetit Spa | The antibiotic rifomycin, its components and methods of preparing same |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4610919A (en) | 1985-06-14 | 1986-09-09 | Fiber Bond Corporation | Binder for fibrous padding |
| JP2544375B2 (ja) | 1986-07-14 | 1996-10-16 | 鐘淵化学工業株式会社 | アルキル置換ベンゾキサジノリフアマイシン誘導体 |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| CA1304363C (en) | 1988-11-01 | 1992-06-30 | Takehiko Yamane | 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
| US5545721A (en) | 1992-12-21 | 1996-08-13 | Ophidian Pharmaceuticals, Inc. | Conjugates for the prevention and treatment of sepsis |
| US6660267B1 (en) | 1992-12-21 | 2003-12-09 | Promega Corporation | Prevention and treatment of sepsis |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5981522A (en) | 1995-09-01 | 1999-11-09 | Kaneka Corporation | Treatment of disease caused by infection of Helicobacter |
| JP3963976B2 (ja) | 1995-12-08 | 2007-08-22 | 株式会社カネカ | クラミジア感染症治療剤 |
| US6322788B1 (en) | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
| ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| US7101692B2 (en) * | 1999-04-15 | 2006-09-05 | The Regents Of The University Of California | Identification of sortase gene |
| WO2000071585A1 (en) | 1999-05-03 | 2000-11-30 | Medarex, Inc. | Human antibodies to staphylococcus aureus |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| EP1331266B1 (en) | 2000-10-06 | 2017-01-04 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| EP1384009B1 (en) * | 2001-06-28 | 2004-07-21 | Freni Brembo S.P.A. | Composite disc for a disc brake having a splittable braking band |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
| US20050123536A1 (en) | 2001-11-20 | 2005-06-09 | Che-Leung Law | Treatment of immunological disorders using anti-dc30 antibodies |
| US7122525B2 (en) * | 2001-11-21 | 2006-10-17 | Activbiotics, Inc. | Targeted therapeutics and uses thereof |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| JPWO2003085119A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法 |
| AU2003236020B2 (en) | 2002-04-09 | 2009-03-19 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in GDP-fucose transport |
| BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
| EP1500400A4 (en) | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT CONTAINING ANTIBODY COMPOSITION |
| US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
| JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
| EP1575514A2 (en) | 2002-07-31 | 2005-09-21 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| PT2357006E (pt) | 2002-07-31 | 2016-01-22 | Seattle Genetics Inc | Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AU2003301882A1 (en) | 2002-11-01 | 2004-06-07 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
| JP2007503439A (ja) | 2003-08-22 | 2007-02-22 | アクティブバイオティクス インコーポレイティッド | リファマイシンアナログおよびそれらの使用法 |
| EP1688439A4 (en) | 2003-10-08 | 2007-12-19 | Kyowa Hakko Kogyo Kk | COMPOSITION OF CONDENSED PROTEINS |
| US20070134759A1 (en) | 2003-10-09 | 2007-06-14 | Harue Nishiya | Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase |
| SG149815A1 (en) * | 2003-11-06 | 2009-02-27 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| AU2004308399A1 (en) | 2003-12-23 | 2005-07-14 | Activbiotics, Inc. | Rifamycin analogs and uses thereof |
| JP5064037B2 (ja) * | 2004-02-23 | 2012-10-31 | ジェネンテック， インコーポレイテッド | 複素環式自壊的リンカーおよび結合体 |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| ES2708763T3 (es) | 2005-07-07 | 2019-04-11 | Seattle Genetics Inc | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
| US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
| WO2007096703A2 (en) * | 2005-08-11 | 2007-08-30 | Targanta Therapeutics Inc. | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections |
| WO2007070613A2 (en) | 2005-12-14 | 2007-06-21 | Activbiotics, Incorporated | Rifamycin analogs and uses thereof |
| AU2008251608B2 (en) * | 2007-05-08 | 2014-03-27 | Genentech, Inc. | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
| NZ584514A (en) | 2007-10-19 | 2012-07-27 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| KR20110017383A (ko) | 2008-05-12 | 2011-02-21 | 스트록스 바이오파마슈티컬스, 엘엘씨 | 황색 포도상구균-특이적 항체 제제 |
| US8524691B2 (en) | 2008-08-13 | 2013-09-03 | The Medicines Company | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections |
| AU2009302582A1 (en) | 2008-10-06 | 2010-04-15 | University Of Chicago | Compositions and methods related to bacterial Eap, Emp, and/or AdsA proteins |
| EP2355805B1 (en) * | 2008-12-10 | 2019-02-13 | Cipla Limited | Rifaximin complexes |
| AU2010271582B2 (en) | 2009-07-15 | 2016-07-28 | Aimm Therapeutics B.V. | Gram-positive bacteria specific binding compounds |
| EP2678037B1 (en) | 2011-02-25 | 2014-12-03 | Lonza Ltd | Branched linker for protein drug conjugates |
| JP6133431B2 (ja) * | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
| DK3004162T3 (da) | 2013-05-31 | 2020-05-18 | Genentech Inc | Anti-væg-teichoin-antistoffer og konjugater |
| WO2014193722A1 (en) * | 2013-05-31 | 2014-12-04 | Genentech, Inc. | Anti-wall teichoic antibodies and conjugates |
| WO2015095227A2 (en) * | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
| HK1222577A1 (zh) * | 2013-12-16 | 2017-07-07 | Genentech Inc. | 擬肽化合物及其抗體藥物偶聯物 |
-
2015
- 2015-12-02 RU RU2017118792A patent/RU2017118792A/ru not_active Application Discontinuation
- 2015-12-02 CA CA2966211A patent/CA2966211A1/en not_active Abandoned
- 2015-12-02 BR BR112017011478-0A patent/BR112017011478A2/pt not_active Application Discontinuation
- 2015-12-02 HK HK18103816.6A patent/HK1244230A1/zh unknown
- 2015-12-02 MX MX2017007231A patent/MX2017007231A/es unknown
- 2015-12-02 KR KR1020177015225A patent/KR20170086542A/ko not_active Withdrawn
- 2015-12-02 EP EP15816304.8A patent/EP3226908A1/en not_active Withdrawn
- 2015-12-02 JP JP2017528877A patent/JP6751393B2/ja not_active Expired - Fee Related
- 2015-12-02 CN CN201580075250.4A patent/CN107249642A/zh active Pending
- 2015-12-02 WO PCT/US2015/063515 patent/WO2016090040A1/en not_active Ceased
-
2017
- 2017-06-02 US US15/612,193 patent/US20180125995A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN107249642A (zh) | 2017-10-13 |
| RU2017118792A (ru) | 2019-01-09 |
| JP2018507166A (ja) | 2018-03-15 |
| WO2016090040A1 (en) | 2016-06-09 |
| BR112017011478A2 (pt) | 2018-02-27 |
| RU2017118792A3 (OSRAM) | 2019-06-14 |
| US20180125995A1 (en) | 2018-05-10 |
| EP3226908A1 (en) | 2017-10-11 |
| JP6751393B2 (ja) | 2020-09-02 |
| CA2966211A1 (en) | 2016-06-09 |
| WO2016090040A9 (en) | 2017-06-29 |
| HK1244230A1 (zh) | 2018-08-03 |
| KR20170086542A (ko) | 2017-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017007055A (es) | Conjugados de anticuerpo rifamicina anti-staphylococcus aureus y usos de estos. | |
| MX2017007231A (es) | Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos. | |
| ZA202107931B (en) | Anti-tau antibodies and methods of use | |
| PH12017500877B1 (en) | ANTI-CD79b ANTIBODIES AND METHODS OF USE | |
| PH12017500861A1 (en) | Anti-interleukin-33 antibodies and uses thereof | |
| PT3522706T (pt) | Composições de bacillus thuringiensis rti545 e métodos de utilização para beneficiar o crescimento de plantas e controlar pragas de plantas | |
| MY176285A (en) | Anti-fcrh5 antibodies | |
| MX2016015162A (es) | Anticuerpos anti - gpc3 e inmunoconjugados. | |
| MX2015012326A (es) | Anticuerpos anti-crth2 y su uso. | |
| MX2017003022A (es) | Anticuerpos anti-cll-1 e inmunoconjugados. | |
| TW201613963A (en) | Anti-JAGGED1 antibodies and methods of use | |
| MX2019012708A (es) | Anticuerpos teicoicos anti-pared y conjugados. | |
| MX369758B (es) | Anticuerpos anti-acido teicoico de pared y conjugados. | |
| MX2019006330A (es) | Anticuerpos anti-tau y metodos de uso. | |
| EP3492591A4 (en) | ANTI-B7-H4 ANTIBODIES | |
| WO2017075173A3 (en) | Anti-factor d antibodies and conjugates | |
| WO2018046997A3 (en) | SYNTHETIC ANTIBODIES AGAINST VEGF AND USES THEREOF | |
| EP3361031A4 (en) | DAMPING DEVICE | |
| MX2016016233A (es) | Anticuerpos anti-lgr5 y sus usos. | |
| EP3483471A4 (en) | DAMPING DEVICE | |
| EP3604517A4 (en) | ANTI-APOA1 ANTIBODIES | |
| EP3674324A4 (en) | ANTI-PODOPLANIN ANTIBODIES | |
| EP3557093A4 (en) | DAMPER DEVICE | |
| EP3447330A4 (en) | SHOCK ABSORBER DEVICE | |
| MX2015010789A (es) | Anticuerpos anti-pcsm. |